Publication:
A noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows

dc.contributor.authorRattanaumpawan P.
dc.contributor.authorUpapan P.
dc.contributor.authorThamlikitkul V.
dc.date.accessioned2021-04-05T03:05:31Z
dc.date.available2021-04-05T03:05:31Z
dc.date.issued2018
dc.date.issuedBE2561
dc.description.abstractObjective We compared the effectiveness of antibiotic postprescription review and authorization (PPRA) determined by infectious disease (ID) clinical fellows with that of trained general pharmacists.Methods We conducted a noninferiority cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital in Bangkok, Thailand. Three wards were randomly assigned to the intervention (ie, the pharmacist PPRA group), and another 3 wards were assigned to the control (ie, the fellow PPRA group). We enrolled all patients in the study wards who received 1 or more doses of the targeted antibiotics: piperacillin/tazobactam, imipenem/cilastatin, and meropenem. The noninferiority margin was 10% for the favorable clinical response and 1.5 defined daily doses (DDDs) for the targeted antibiotics.Results We enrolled 303 patients in the pharmacist PPRA group and 307 patients in the ID fellow PPRA group. The baseline and clinical characteristics were similar in the 2 groups. The difference in the favorable response of patients who received the targeted antibiotics (ie, the pharmacist PPRA group minus the fellow PPRA group) was 5.15% (95% confidence interval [CI], -2.69% to 12.98%); the difference in the DDD of targeted antibiotic use (ie, the pharmacist PPRA group minus the fellow PPRA group) was 0.62 (95% CI, -1.57 to 2.82). We observed no significant difference in the DDD of overall antibiotics, 28-day mortality, 28-day ID-related mortality, favorable microbiological outcome, or antibiotic-associated complications.Conclusions We confirmed the noninferiority of pharmacist PPRA in terms of favorable clinical response; however, noninferiority in targeted antibiotic consumption could not be established. Therefore, using trained general pharmacists rather than ID clinical fellows could be an alternative in a resource-limited setting. Clinical trials registration: clinicaltrials.gov identifier: NCT 01797133 © 2018 by The Society for Healthcare Epidemiology of America. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationInfection Control and Hospital Epidemiology. Vol 39, No.10 (2018), p.1154-1162
dc.identifier.doi10.1017/ice.2018.198
dc.identifier.issn0899823X
dc.identifier.other2-s2.0-85053002289
dc.identifier.urihttps://hdl.handle.net/20.500.14740/5835
dc.rights.holderScopus
dc.subject.otherCilastatin plus imipenem
dc.subject.otherMeropenem
dc.subject.otherPiperacillin plus tazobactam
dc.subject.otherPrescription drug
dc.subject.otherAntiinfective agent
dc.subject.otherAdult
dc.subject.otherAntibiotic associated colitis
dc.subject.otherAntibiotic postprescription review and authorization
dc.subject.otherAntibiotic prophylaxis
dc.subject.otherAntibiotic therapy
dc.subject.otherAntimicrobial stewardship
dc.subject.otherBone infection
dc.subject.otherCardiovascular infection
dc.subject.otherCatheter infection
dc.subject.otherCentral nervous system infection
dc.subject.otherClinical outcome
dc.subject.otherColitis
dc.subject.otherCommunity acquired infection
dc.subject.otherComparative effectiveness
dc.subject.otherControlled study
dc.subject.otherDrug cost
dc.subject.otherDrug hypersensitivity
dc.subject.otherDrug induced disease
dc.subject.otherDrug response
dc.subject.otherDrug use
dc.subject.otherDrug utilization review
dc.subject.otherFemale
dc.subject.otherGastrointestinal infection
dc.subject.otherGenital tract infection
dc.subject.otherHead and neck infection
dc.subject.otherHospital infection
dc.subject.otherHospital mortality
dc.subject.otherHospital patient
dc.subject.otherHuman
dc.subject.otherInfectious arthritis
dc.subject.otherInfectious disease clinical fellow
dc.subject.otherIntervention study
dc.subject.otherLength of stay
dc.subject.otherMajor clinical study
dc.subject.otherMale
dc.subject.otherMedical education
dc.subject.otherMiddle aged
dc.subject.otherMulticenter study
dc.subject.otherNose infection
dc.subject.otherPharmacist
dc.subject.otherPharyngitis
dc.subject.otherPhysician
dc.subject.otherPneumonia
dc.subject.otherPrescription
dc.subject.otherRandomized controlled trial
dc.subject.otherReview
dc.subject.otherSkin infection
dc.subject.otherSoft tissue infection
dc.subject.otherSurgical infection
dc.subject.otherThailand
dc.subject.otherTreatment response
dc.subject.otherUrinary tract infection
dc.subject.otherAged
dc.subject.otherCommunicable disease
dc.subject.otherHealth care facility
dc.subject.otherHealth care quality
dc.subject.otherHospital pharmacy
dc.subject.otherOrganization and management
dc.subject.otherPharmacist
dc.subject.otherProcedures
dc.subject.otherStandards
dc.subject.otherVery elderly
dc.subject.otherAdult
dc.subject.otherAged
dc.subject.otherAged, 80 and over
dc.subject.otherAnti-Bacterial Agents
dc.subject.otherAntimicrobial Stewardship
dc.subject.otherCommunicable Diseases
dc.subject.otherFemale
dc.subject.otherHumans
dc.subject.otherMale
dc.subject.otherMiddle Aged
dc.subject.otherPatients' Rooms
dc.subject.otherPharmacists
dc.subject.otherPharmacy Service, Hospital
dc.subject.otherStandard of Care
dc.subject.otherThailand
dc.titleA noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053002289&doi=10.1017%2fice.2018.198&partnerID=40&md5=75e55793c32aed276d014061738c46e3

Files